Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 183-187

  Mancini, N ^a,b   Canducci, F ^b   Carletti, S ^b   Berardinelli, E ^a   Serafini, G ^a   Grieco, A ^a   Perotti, M ^a   Malcangi, G ^a   Danieli, M G ^a   Varaldo, P E ^a   Clementi, M ^b   Burioni, Roberto ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antibody response; Fab inhibition titer; HCV E2; Monoclonal fab

Indexed keywords

EPITOPE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; VIRUS PROTEIN;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; MICROBIOLOGICAL PARAMETERS; MOLECULAR MECHANICS; NONHUMAN; PERSISTENT VIRUS INFECTION;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 12444270693     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Manzin A, Solforosi L, Debiaggi M, et al. Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J Virol 2000; 74: 4327-34.
3. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-44.
4. Farci P, Purcell RH. Clinical Significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20: 103-26.
5. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135-40.
6. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388-90.
7. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792-6.
8. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 1995; 208: 653-61.
9. Piazza M, Sagliocca L, Tosone G, et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997; 157: 1537-44.
10. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-11.
11. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-8.
12. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93: 15394-9.
13. Ishii K, Rosa D, Watanabe Y, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998; 28: 1117-20.
14. Burioni R, Plaisant P, Manzin A, et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 1998; 28: 810-4.
15. Hadlock KG, Lanford RE, Perkins S, et al. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 2000; 74: 10407-16.
16. Plaisant P, Burioni R, Manzin A, et al. Human monoclonal recombinant Fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors. Res Virol 1997; 148: 165-9.
17. Burioni R, Matsuura Y, Mancini N, et al. Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype. J Virol 2002; 76: 11775-9.
18. Lesniewski R, Okasinski G, Carrick R, et al. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: A new marker of HCV infection closely associated with viremia. J Med Virol 1995; 45: 415-22.
19. Burioni R, Bugli F, Mancini N, et al. A novel expression vector for production of epitope-tagged recombinant Fab fragments in bacteria. Hum Antibodies 2001; 10: 149-54.